Chemotherapy News and Research

Latest Chemotherapy News and Research

Adolescent and young adult patients with ALL fare better with high-intensity pediatric protocols

Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients--aged 16 to 39 with acute lymphoblastic leukemia (ALL)--tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.

8 Dec 2014

New type of cancer therapy shows promise in patients with advanced leukemia

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial. The study, led by Eytan M. Stein, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, was presented today at the 56th Annual Meeting of the American Society of Hematology.

8 Dec 2014

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Having simultaneous chemotherapy and breast reconstruction after mastectomy may rise complications

Immediate breast reconstruction following mastectomy is becoming more prevalent. However, in breast cancer patients undergoing simultaneous chemotherapy, thrombotic complications can arise that can delay or significantly modify reconstructive plans. Outcomes of cases illustrating potential complications are published in the current issue of Annals of Medicine and Surgery.

7 Dec 2014

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so.

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.

7 Dec 2014

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Cancers are due to genetic aberrations in certain cells that gain the ability to divide indefinitely. This proliferation of sick cells generates tumors, which gradually invade healthy tissue. Therefore, current therapies essentially seek to destroy cancer cells to stop their proliferation. Through high-throughput genetic sequencing of glioblastoma cells, one of the most deadly brain tumors, a team of geneticists from the University of Geneva's (UNIGE) Faculty of Medicine discovered that some of these mutations are caused by supplemental extrachromosomal DNA fragments, called double minutes, which enable cancer cells to better adapt to their environment and therefore better resist to treatments meant to destroy them.

6 Dec 2014

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Zeltia announces today that its pharmaceutical division PharmaMar has data from a group of 33 randomized patients with platinum-resistant ovarian cancer demonstrating that PM1183 shows a significantly superior median overall survival compared to topotecan.

4 Dec 2014

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinabulin, in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2015.

4 Dec 2014

New targeted therapy shows promise in patients with ALK-positive advanced NSCLC

An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.

4 Dec 2014

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

While aptamers—single-stranded nucleic acids—offer promise as drug-delivery tools for cancer treatment, it has proven difficult to get them to tumor cells at therapeutic levels.

4 Dec 2014

Researchers identify biochemical mechanism that could lead to 'chemo brain'

UNC School of Medicine researchers have found for the first time a biochemical mechanism that could be a cause of "chemo brain" - the neurological side effects such as memory loss, confusion, difficulty thinking, and trouble concentrating that many cancer patients experience while on chemotherapy to treat tumors in other parts of the body.

4 Dec 2014

Organovo, Yale collaborate to develop bioprinted tissues for surgical transplantation research

Organovo Holdings, Inc., a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, and Yale School of Medicine, Department of Surgery have formed a collaboration to develop bioprinted tissues for surgical transplantation research, made possible by a generous gift from the Methuselah Foundation.

3 Dec 2014

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the Company has received written notice from the United States Food and Drug Administration that its clinical trials for aldoxorubicin have been placed on partial clinical hold.

3 Dec 2014

New WHO guidance provides cervical cancer control and prevention approach

New guidance from WHO aims to help countries better prevent and control cervical cancer. The disease is one of the world's deadliest - but most easily preventable - forms of cancer for women, responsible for more than 270 000 deaths annually, 85% of which occur in developing countries.

3 Dec 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

Adolescent and young adult patients with ALL fare better with high-intensity pediatric protocols

New type of cancer therapy shows promise in patients with advanced leukemia

Novel targeted therapies and treatment combinations for leukemia

Having simultaneous chemotherapy and breast reconstruction after mastectomy may rise complications

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Researchers identify new targets for future CLL therapies

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

New targeted therapy shows promise in patients with ALK-positive advanced NSCLC

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

Researchers identify biochemical mechanism that could lead to 'chemo brain'

Organovo, Yale collaborate to develop bioprinted tissues for surgical transplantation research

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

New WHO guidance provides cervical cancer control and prevention approach

Study finds that cancer cells may be susceptible to metabolic stress

Antacid medicines improve overall survival in patients with head and neck cancer

Mayo Clinic recommends genetic screening for patients with triple-negative breast cancer

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in